On March 26, 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2025. The AACR (Free AACR Whitepaper) Annual Meeting will be held at the McCormick Place in Chicago, Illinois, from April 25–30, 2025 (Press release, Puma Biotechnology, MAR 26, 2025, View Source [SID1234651498]). The title of the poster that will be presented is now available on the AACR (Free AACR Whitepaper) Annual Meeting website at View Source!/20273/presentation/10447. The full poster will be available on the Puma website concurrent with the live presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Session: First-in-Human Phase I Clinical Trials 1

Abstract CT071: Title: Phase I trial of trastuzumab deruxtecan in combination with neratinib in solid tumors with HER2 alterations (NCI 10495)
Authors: Andrew A. Davis, Haeseong Park, Ecaterina E. Dumbrava, Nataliya V. Uboha, Aparna Kalyan, Farshid Dayyani, Mili Arora, Miguel A. Villalona-Calero, Haider S. Mahdi, Reema A. Patel, Floor Backes, Jessica Porzel, Whitney L. Hensing, Cheryl Pickett, Cynthia X. Ma, Ron Bose
Presenter: Andrew Davis, MD, Washington University School of Medicine
Date/Time: April 28, 2025, 2:00–5:00 p.m. CT